RNS Number:5849D
BioProgress PLC
01 October 2004



Press Release                                             1 October 2004


                             BioProgress Plc

                     ("BioProgress" or the "Company")
 
      High Court victory for BioProgress in Patent Entitlement case


In a 100 per cent victory in a dispute with Stanelco Fibre Optics Limited,
BioProgress Technology Limited, a wholly owned subsidiary of BioProgress plc
(LSE: AIM: BPRG), has been awarded outright ownership of the master patent that
gives it exclusive worldwide rights to the process of making capsules from non-
gelatin materials by means of radio frequency ("RF").


This master patent controls the group of patents that were the subject of this
case and no commercial exploitation of the patented technology is permissible
without the consent of BioProgress.


The Court also found that discussions between BioProgress and Stanelco in the
summer of 1998 were subject to confidentiality.  The Judge held that because
Stanelco had misused information given to them in confidence by BioProgress,
Stanelco had breached an obligation of confidence owed, by founding their own
family of patents and patent applications to the technology based on
BioProgress' core inventive concept.


There will now be a further hearing to determine the mechanism of transfer of
ownership of the main patent to BioProgress, together with all other patents and
patent applications worldwide which are derived from the original main patent
filing.  In addition, the Court will be asked to assess the damages to be
awarded to BioProgress for Stanelco's misuse of BioProgress' confidential
information.


Graham Hind, CEO of BioProgress, said: "This judgement validates the position we
have taken during the proceedings.  The technology will strengthen significantly
our position in the global encapsulation market and adds significant revenue
earning potential to our SWALLOTM. liquid capsule technologies.


"By combining the intellectual property in this patent with our existing
technologies, BioProgress will now be able to deliver an even more
cost-effective, product enhancing, animal free solution to the encapsulation of
liquids which is a truly large global market."


                                    - Ends -


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  This announcement contains certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995.  These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances.  Actual results may
vary materially from the expectations contained in the forward-looking
statements.  The forward-looking statements in this release include statements
addressing future financial and operating results and the timing and benefits of
the reorganisation.  Detailed information about factors pertinent to the
business of the company that could cause actual results to differ is set forth
in the Company's filings with the Securities and Exchange Commission.  The
Company is under no obligation to (and expressly disclaim any such obligation
to) update or alter its forward-looking statements whether as a result of new
information, future events or otherwise.


                                    - Ends -



For further information:

BioProgress plc

Barry Muncaster, Consultant                             Tel: +44 (0) 7785 902678
bjm@bioprogress.com

Graham Hind, Chief Executive                            Tel: +44 (0) 1354 655674
grahamhind@bioprogress.com                                   www.bioprogress.com

Media enquiries:

Abchurch

Alex Tweed / Heather Salmond                           Tel: +44 (0) 20 7398 7700
alex.tweed@abchurch-group.com                             www.abchurch-group.com


Notes to editors:


BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company's patent portfolio comprises over 80 patents within
twenty-four patent families and has product development agreements and strategic
alliances with several global companies.  BioProgress aims to provide a cost
effective and animal-free encapsulation process for pharmaceutical drugs in
liquids, tablets and powders, thereby addressing the needs of the entire market
for oral dosage forms while providing novel delivery mechanisms not possible
with traditional processes.


The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually.


The Company's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCMBBMTMMAMBFI
Stanelco (LSE:SEO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Stanelco Charts.
Stanelco (LSE:SEO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Stanelco Charts.